AstraZeneca Expands China Partnerships with Up to $2.1bn Respiratory Drug Deal

The agreement with Sino Biopharmaceutical gives AstraZeneca ex-China rights to TQC3721, an experimental dual PDE3/4 inhibitor being developed for chronic respiratory diseases.

AstraZeneca has entered into a new collaboration with China’s Sino Biopharmaceutical focused on the development of TQC3721, an experimental respiratory therapy that could be worth up to $2.1 billion in upfront, milestone and royalty payments.

The agreement continues AstraZeneca’s recent run of strategic partnerships in China and highlights the growing importance of Chinese biopharma companies as sources of innovative pipeline assets for multinational drugmakers.

Deal Terms and Scope

Under the agreement, AstraZeneca will pay Sino Biopharmaceutical $200 million upfront for exclusive rights to develop, manufacture and commercialise TQC3721 outside China.

Sino is eligible to receive up to $1.9 billion in additional development and commercial milestone payments, alongside tiered sales royalties that may reach double-digit percentages.

AstraZeneca will also gain exclusive global rights to certain future development programmes related to the therapy.

A Dual PDE3/4 Approach for Respiratory Disease

TQC3721 is designed to inhibit both phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4), a mechanism intended to combine bronchodilatory and anti-inflammatory effects.

According to Sino Biopharmaceutical, the therapy has the potential to improve lung function, reduce exacerbations and address broader disease burden in patients with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD).

A nebulised formulation of TQC3721 demonstrated what the company described as a “potential best-in-class profile” in a Phase IIb study in COPD.

The nebulised version is currently being evaluated in a Phase III study in China, while a dry-powder inhaler formulation is also being advanced in a Phase II clinical trial.

Accelerating Global Development

Sino Biopharmaceutical said the partnership with AstraZeneca is expected to accelerate the global clinical development of TQC3721 and maximise the therapy’s clinical and commercial potential.

For AstraZeneca, the deal strengthens its respiratory pipeline by adding a late-stage Chinese asset with potential applications in chronic respiratory disease management.

The collaboration also reflects a broader strategy of sourcing innovative medicines from China for development and commercialisation in international markets.

Part of a Wider China Strategy

The TQC3721 agreement is AstraZeneca’s latest collaboration with a Chinese pharmaceutical company.

Just days earlier, the company expanded its relationship with CSPC Pharmaceutical through a deal focused on siRNA drug discovery for renal diseases, with potential milestone payments approaching $1.8 billion.

AstraZeneca has built a particularly active partnership network in China, including multiple agreements with CSPC Pharmaceutical since 2024, spanning renal disease, obesity, type 2 diabetes and other therapeutic areas.

Sino Biopharmaceutical’s Growing Global Role

The AstraZeneca agreement marks Sino Biopharmaceutical’s second major out-licensing deal with a multinational pharmaceutical company in 2026, following an earlier agreement with Sanofi involving the experimental oral JAK/ROCK inhibitor rovadicitinib.

The company also announced an expansion of its collaboration with GSK to commercialise the respiratory therapies Trelegy Ellipta and Anoro Ellipta in China through its Chia Tai Tianqing Pharmaceutical unit.

These parallel agreements underscore Sino Biopharmaceutical’s dual strategy of out-licensing innovative pipeline assets globally while leveraging its commercial infrastructure to expand access to established respiratory therapies within China.

Strategic Implications

The deal highlights several trends shaping the pharmaceutical industry:

• Chinese biopharma companies are becoming increasingly important sources of innovative drug candidates.

• Multinational pharmaceutical companies are using partnerships to access regional innovation and accelerate global development.

• Respiratory disease remains a significant area of unmet medical need and commercial opportunity.

• China is playing a growing role not only as a market for commercialised medicines but also as a contributor to global drug discovery and development.

  
  

Summary

AstraZeneca has secured exclusive rights outside China to develop and commercialise Sino Biopharmaceutical’s experimental respiratory therapy TQC3721 in a deal worth up to $2.1 billion.

The agreement adds a dual PDE3/4 inhibitor programme to AstraZeneca’s respiratory pipeline and reinforces the company’s expanding strategy of partnering with Chinese biopharma firms to access innovative medicines for global markets.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com